An anti-CD20 × anti-CD3 T-cell–redirecting bispecific monoclonal antibody that engages CD3+ T cells and CD20+ B cells to induce cytotoxicity in malignant B cells.
Bispecific anti-CD20×anti-CD3 antibody that simultaneously binds CD20 on B cells and CD3 on T cells, crosslinking them to form an immune synapse and activate T cells to kill CD20+ malignant B cells via redirected cytotoxicity (perforin/granzyme and cytokine-mediated effects).
NO
INDIRECT
CD3 on T cells is engaged to activate and redirect T cells; these T cells kill CD20+ B cells via perforin/granzyme and cytokine-mediated cytotoxicity, not the CD3+ cells.
An anti-CD22 × anti-CD28 costimulatory bispecific monoclonal antibody that binds CD22 on B cells and CD28 on T cells to deliver CD28 costimulation without independent T-cell activation; a costimulatory T-cell–engager.
Costimulatory bispecific IgG4 antibody that binds CD22 on B cells and CD28 on T cells to deliver CD28 costimulation without independent T-cell activation. By crosslinking T cells to CD22+ tumor cells, it provides CD28 costimulatory signaling in the context of TCR engagement, enhancing cytotoxic T-lymphocyte activation and killing of CD22-expressing B-cell malignancies.
YES
DIRECT
The bispecific binds CD22 on tumor cells and CD28 on T cells to provide CD28 costimulation; with concurrent TCR/CD3 engagement, this activates cytotoxic T cells to kill CD22+ cells via perforin/granzyme-mediated apoptosis.
An anti-CD22 × anti-CD28 costimulatory bispecific monoclonal antibody that binds CD22 on B cells and CD28 on T cells to deliver CD28 costimulation without independent T-cell activation; a costimulatory T-cell–engager.
Costimulatory bispecific IgG4 antibody that binds CD22 on B cells and CD28 on T cells to deliver CD28 costimulation without independent T-cell activation. By crosslinking T cells to CD22+ tumor cells, it provides CD28 costimulatory signaling in the context of TCR engagement, enhancing cytotoxic T-lymphocyte activation and killing of CD22-expressing B-cell malignancies.
NO
INDIRECT
The bispecific binds CD28 on T cells and CD22 on B cells to provide CD28 costimulation, enabling TCR-mediated killing of CD22+ tumor cells. CD28-expressing T cells are not the cells killed.
Oral HER2-selective tyrosine kinase inhibitor that blocks HER2 phosphorylation and downstream PI3K/AKT and RAS/RAF/MEK/ERK signaling; designed to spare EGFR.
Oral, irreversible HER2-selective tyrosine kinase inhibitor that binds and inhibits HER2 and HER2 mutants (including exon 20 insertions), blocking HER2 phosphorylation and downstream PI3K/AKT and RAS/RAF/MEK/ERK signaling, while sparing wild‑type EGFR; this suppresses proliferation and can induce death in HER2-expressing tumor cells.
YES
DIRECT
Irreversible HER2 kinase inhibition blocks HER2 phosphorylation and downstream PI3K/AKT and RAS/RAF/MEK/ERK signaling, leading to growth arrest and apoptotic death of HER2-expressing tumor cells.
Oral HER2-selective tyrosine kinase inhibitor that blocks HER2 phosphorylation and downstream PI3K/AKT and RAS/RAF/MEK/ERK signaling; designed to spare EGFR.
Oral, irreversible HER2-selective tyrosine kinase inhibitor that binds and inhibits HER2 and HER2 mutants (including exon 20 insertions), blocking HER2 phosphorylation and downstream PI3K/AKT and RAS/RAF/MEK/ERK signaling, while sparing wild‑type EGFR; this suppresses proliferation and can induce death in HER2-expressing tumor cells.
YES
DIRECT
Irreversible small‑molecule HER2 TKI that binds and inhibits mutant HER2 (including exon 20 insertions), blocking PI3K/AKT and RAS/RAF/MEK/ERK signaling and inducing growth arrest and apoptosis of HER2‑mutant tumor cells.